Table 1.

Baseline characteristics of the 9 patients with SSc enrolled.

Data at Pretreatment
PatientSex/Age at Entry, yrsSSc SubsetANAILD Stage*Disease Duration, mo%FVC% TLC% DLCOTRPG, mmHgMRSSReason for Not Using CYC
1M 29dcSScTopo IE255362443630Severely impaired lung function
2F 63dcSScTopo IE365857233920Relapse after CYC treatment
3F 65dcSScTopo IE293657630257Long disease duration
4M 36dcSScTopo IE364453532914Severely impaired lung function
5F 54dcSScTopo IE2973442185325Severely impaired lung function
6M 62lcSScTh/ToE167243716382Severely impaired lung function
7F 31lcSScU1RNPE72626822302Patient refusal
8M 77lcSScU1RNPL10776740274Recent malignancy
9F 79lcSScU1RNPE3381078134302Long disease duration
  • * E: extensive disease; L: limited disease.

  • Disease duration from first non-Raynaud’s phenomenon. SSc: systemic sclerosis; dcSSc: diffuse cutaneous SSc: lcSSc: limited cutaneous SSc; ANA: antinuclear antibody; TOPO I: topoisomerase I; U1RNP: U1 ribonucleoprotein; FVC: forced vital capacity; TLC: total lung capacity; DLCO: diffusing capacity for carbon monoxide; TRPG: tricuspid regurgitation pressure gradient; MRSS: modified Rodnan skin thickness score; CYC: cyclophosphamide.